Company
Our mission is to create real hopes
through innovative new drug developments
About the Company
  • HOME
  • Company
  • About the Company
Pinotbio conducts R&D on an ADC platform, a best-in-class targeted anticancer drug, and a glaucoma medicine.

We are a biotech company developing new treatments for patients resistant to existing therapies based on innovative new drug modalities such as antibody-drug conjugate(ADC).

Based on our strong R&D capabilities, we have built our next-generation ADC platform PINOT-ADC™ independently and have been working with various partners to research new ADC anticancer treatments. In addition, clinical development and commercialization of NTX-301, a targeted anticancer drug for blood/solid cancer, and NTX-101, a treatment for glaucoma, are underway.

MISSON & VISION
Present patients with sustainable hope
  • ADC Platform

    Next Generation ADC Platform Technology

    Payload and Linker that can overcome resistance

    Next-Gen Targeted
    Anticancer Therapy

    Clinical safety and efficacy has been confirmed for NTX-301

    Dual action, exerting powerful anticancer effect

  • Multi-mechanism,
    multi-target
    Anticancer drugs
  • Global Leading Biotech for
    Novel Anticancer
    Treatment